New trial
Phase I/II bortezomib 26S proteasome inhibitor with CPX-351 in TP53-mutated AML
- Trial ID
- NCT07008638 on ClinicalTrials.gov
- Cancer type
- AML: Acute Myeloid Leukemia
- Stage of research
- Exploratory
- Published in
- New in Oncology - Aug 1, 2025
This trial by the Masonic Cancer Center, University of Minnesota evaluates safety and preliminary efficacy of bortezomib (a 26S proteasome inhibitor) combined with CPX-351 (a liposomal formulation of daunorubicin and cytarabine) in patients with newly-diagnosed TP53-mutated AML. It aims to attenuate NF-kB activation and eradicate TP53-mutated leukemia stem cells while assessing remission, survival, and treatment feasibility.
More in acute myeloid leukemia and MDS
-
Trial result · Oct 22, 2026 · NCT03672539
CPX-351 (liposomal daunorubicin/cytarabine) + CD33-targeted gemtuzumab ozogamicin delivers 19% CRc in heavily pretreated R/R AML -
New trial · Oct 15, 2026 · NCT07809906
Phase 1 ORM-1153 CD123-directed degrader-antibody conjugate delivers a GSPT1-degrading payload in hematologic malignancies -
Trial result · Sep 17, 2026 · NCT02159495
CD123 CAR-T Delivers ~27% CR/CRi in Post-alloHCT AML With Manageable CRS/Neurotoxicity -
New trial · Sep 10, 2026 · NCT07581002
Phase 2/3 Pivekimab sunirine CD123-targeted ADC (IGN payload) + venetoclax/azacitidine in AML -
New trial · Sep 10, 2026 · NCT07780565
Phase 1b monzosertib CDC7 kinase inhibitor tests azole–drug interaction dosing in AML/MDS